GR3029837T3 - Process for extracting high-purity von willebrand factor - Google Patents
Process for extracting high-purity von willebrand factorInfo
- Publication number
- GR3029837T3 GR3029837T3 GR990400931T GR990400931T GR3029837T3 GR 3029837 T3 GR3029837 T3 GR 3029837T3 GR 990400931 T GR990400931 T GR 990400931T GR 990400931 T GR990400931 T GR 990400931T GR 3029837 T3 GR3029837 T3 GR 3029837T3
- Authority
- GR
- Greece
- Prior art keywords
- von willebrand
- willebrand factor
- rvwf
- free
- highly pure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4435485A DE4435485C1 (de) | 1994-10-04 | 1994-10-04 | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
PCT/EP1995/003892 WO1996010584A1 (de) | 1994-10-04 | 1995-10-02 | Verfahren zur gewinnung von hochreinem von willebrand-faktor |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3029837T3 true GR3029837T3 (en) | 1999-06-30 |
Family
ID=6529944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR990400931T GR3029837T3 (en) | 1994-10-04 | 1999-03-31 | Process for extracting high-purity von willebrand factor |
Country Status (11)
Country | Link |
---|---|
US (4) | US5854403A (el) |
EP (1) | EP0784632B1 (el) |
JP (1) | JP3701028B2 (el) |
AT (1) | ATE175424T1 (el) |
AU (1) | AU698334B2 (el) |
CA (1) | CA2201714C (el) |
DE (2) | DE4435485C1 (el) |
DK (1) | DK0784632T3 (el) |
ES (1) | ES2128090T3 (el) |
GR (1) | GR3029837T3 (el) |
WO (1) | WO1996010584A1 (el) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880327A (en) * | 1994-09-21 | 1999-03-09 | American National Red Cross | Transgenic mammals expressing human coagulation factor VIII |
DE19616540A1 (de) * | 1995-11-10 | 1997-05-15 | Immuno Ag | Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung |
US6005077A (en) * | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
US6068838A (en) * | 1996-04-29 | 2000-05-30 | Baxter Aktiengesellschaft | Purified multimerase |
AT406867B (de) | 1997-02-27 | 2000-10-25 | Immuno Ag | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
DE69941157D1 (de) | 1998-09-21 | 2009-09-03 | Howard E Purdum | Verfahren und vorrichtung zur behandlung von blutplasma oder blutplasmakonzentrat |
AU7619500A (en) * | 1999-09-28 | 2001-04-30 | Us Transgenics, Inc. | Transgenic vwf and vwf-related polypeptides, transgenics, methods, compositions,uses and the like relating thereto |
US20040185042A1 (en) * | 2003-03-20 | 2004-09-23 | Friedrich Scheiflinger | Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies |
EP1642128B1 (en) * | 2003-07-07 | 2016-11-16 | University Of North Carolina At Chapel Hill | Method and system for detection of von willebrand factor (vwf) multimers |
US7771660B2 (en) * | 2004-05-04 | 2010-08-10 | University Of North Carolina At Chapel Hill | Electrophoretic interactive spectral methods and devices for the detection and/or characterization of biological particles |
FR2874216B1 (fr) * | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
CA2579374A1 (en) | 2004-09-07 | 2006-03-30 | Archemix Corp. | Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
CA2578046A1 (en) | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
EP1835938B1 (en) | 2004-12-27 | 2013-08-07 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
WO2008150495A2 (en) * | 2007-06-01 | 2008-12-11 | Archemix Corp. | Vwf aptamer formulations and methods for use |
EP2486936A1 (en) | 2007-06-13 | 2012-08-15 | CSL Behring GmbH | A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders |
FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
EP2073015A1 (en) | 2007-12-21 | 2009-06-24 | CSL Behring GmbH | Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function |
US20100273206A1 (en) * | 2007-12-21 | 2010-10-28 | Manfred Rauh | Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function |
US11197916B2 (en) * | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
JP5784907B2 (ja) | 2007-12-28 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 組換え型vwf製剤 |
AU2014202595A1 (en) * | 2007-12-28 | 2014-06-05 | Baxalta GmbH | Recombinant VWF Formulations |
CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
CA2740919A1 (en) * | 2008-10-21 | 2010-04-29 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
US20120148557A1 (en) | 2009-08-20 | 2012-06-14 | Ulrich Kronthaler | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
MX2012005527A (es) | 2009-11-13 | 2012-08-08 | Grifols Therapeutics Inc | Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas. |
WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
EP2652491B1 (en) | 2010-12-15 | 2017-11-29 | Baxalta GmbH | Eluate collection using conductivity gradient |
EP3412305B1 (en) * | 2011-06-10 | 2021-01-06 | Baxalta GmbH | Treatment of coagulation disease by administration of recombinant vwf |
EP2748180B1 (en) * | 2011-10-14 | 2018-08-15 | Baxalta GmbH | Protein purification by anion exchange chromatography |
AU2012318279B2 (en) | 2011-10-18 | 2015-06-04 | Csl Behring Gmbh | Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII |
JP6029674B2 (ja) | 2011-10-18 | 2016-11-24 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第viii因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用 |
EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
US20140206844A1 (en) | 2013-01-18 | 2014-07-24 | Prothera Biologics | Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material |
DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
CN105705516B (zh) | 2013-11-08 | 2019-11-01 | 杰特有限公司 | 浓缩von Willebrand因子或其络合物的方法 |
ES2844232T3 (es) | 2014-07-02 | 2021-07-21 | CSL Behring Lengnau AG | Factor de Von Willebrand modificado |
US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
SG10201912498YA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated truncated von willebrand factor |
EP3400238B1 (en) | 2016-01-07 | 2021-05-19 | CSL Behring Lengnau AG | Mutated von willebrand factor |
US10632176B2 (en) | 2017-07-07 | 2020-04-28 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF |
BR112020002234A2 (pt) | 2017-08-23 | 2020-07-28 | Csl Behring Gmbh | método para a filtragem de virus do fator von willebrand |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
NL8500961A (nl) * | 1985-04-01 | 1986-11-03 | Stichting Vrienden Van De Stic | Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten. |
FR2632309B1 (fr) * | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
DE3904354A1 (de) * | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
FR2665449B1 (fr) * | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. |
ATE138575T1 (de) * | 1989-06-15 | 1996-06-15 | Rorer Int Overseas | Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen |
FR2651437A1 (fr) * | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
US5312747A (en) * | 1990-12-17 | 1994-05-17 | Li Yu Teh | Isolation, purification and utilization of sialidase-L in the synthesis of 2,7-anhydro-N-acetylneuraminic acid and for the selective cleavage of sialylα2-3 D-galactose linkage |
FR2673632A1 (fr) * | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
IT1256622B (it) * | 1992-12-04 | 1995-12-12 | Sclavo Spa | Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale. |
JP3133338B2 (ja) * | 1992-12-16 | 2001-02-05 | イムノ・アクチエンゲゼルシャフト | ウイルス的に安全な生物学的組成物の調製方法 |
DE4434538C2 (de) * | 1993-10-06 | 2000-08-10 | Immuno Ag | Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens |
-
1994
- 1994-10-04 DE DE4435485A patent/DE4435485C1/de not_active Expired - Fee Related
-
1995
- 1995-10-02 AT AT95935890T patent/ATE175424T1/de active
- 1995-10-02 JP JP51140796A patent/JP3701028B2/ja not_active Expired - Fee Related
- 1995-10-02 DK DK95935890T patent/DK0784632T3/da active
- 1995-10-02 DE DE59504750T patent/DE59504750D1/de not_active Expired - Lifetime
- 1995-10-02 AU AU38031/95A patent/AU698334B2/en not_active Ceased
- 1995-10-02 WO PCT/EP1995/003892 patent/WO1996010584A1/de active IP Right Grant
- 1995-10-02 ES ES95935890T patent/ES2128090T3/es not_active Expired - Lifetime
- 1995-10-02 CA CA002201714A patent/CA2201714C/en not_active Expired - Fee Related
- 1995-10-02 EP EP95935890A patent/EP0784632B1/de not_active Expired - Lifetime
-
1996
- 1996-05-24 US US08/653,298 patent/US5854403A/en not_active Expired - Lifetime
-
1997
- 1997-07-22 US US08/898,130 patent/US6103693A/en not_active Expired - Lifetime
- 1997-07-22 US US08/898,129 patent/US5880265A/en not_active Expired - Lifetime
- 1997-07-22 US US08/898,131 patent/US5877152A/en not_active Expired - Lifetime
-
1999
- 1999-03-31 GR GR990400931T patent/GR3029837T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE4435485C1 (de) | 1996-03-21 |
US6103693A (en) | 2000-08-15 |
AU698334B2 (en) | 1998-10-29 |
WO1996010584A1 (de) | 1996-04-11 |
EP0784632A1 (de) | 1997-07-23 |
ES2128090T3 (es) | 1999-05-01 |
ATE175424T1 (de) | 1999-01-15 |
DE59504750D1 (de) | 1999-02-18 |
US5880265A (en) | 1999-03-09 |
CA2201714C (en) | 2002-07-02 |
EP0784632B1 (de) | 1999-01-07 |
JP3701028B2 (ja) | 2005-09-28 |
US5854403A (en) | 1998-12-29 |
CA2201714A1 (en) | 1996-04-11 |
AU3803195A (en) | 1996-04-26 |
DK0784632T3 (da) | 1999-08-30 |
JPH11509721A (ja) | 1999-08-31 |
US5877152A (en) | 1999-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3029837T3 (en) | Process for extracting high-purity von willebrand factor | |
US6399333B1 (en) | Process for producing erythropoietin containing no animal proteins | |
Ebert | Amino acid analysis by HPLC: optimized conditions for chromatography of phenylthiocarbamyl derivatives | |
CA2065553C (en) | Stabilized factor viii preparations | |
IE860305L (en) | Method for purifying antihemophilic factor | |
RU93046317A (ru) | Хиндроитиназа, способ ее получения и содержание ее фармацевтические композиции | |
JP3787154B2 (ja) | Viii因子の精製方法 | |
Calvete et al. | A procedure for the large-scale isolation of major bovine seminal plasma proteins | |
BG101106A (en) | Medicamentous forms of risperidon in aqueous solution | |
KR920701255A (ko) | 에리쓰로포이에틴 동형체(eryihropoietin isoform) | |
NZ509135A (en) | A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods | |
BR9913026A (pt) | Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano | |
US5252710A (en) | Process for manufacturing von Willebrand factor | |
RU2002117383A (ru) | Способ очистки фармакологически активных белков с помощью катионообменной хроматографии | |
EP0228452B1 (en) | Protein purification | |
US6831159B1 (en) | Method for purifying factor VIII/vWF company by cation-exchange chromatography | |
CA2293806A1 (en) | Alpha 1-antitrypsin preparation as well as a method for producing the same | |
AU1348188A (en) | New cardiodilatin fragment, process for preparing same and use thereof | |
US5371195A (en) | Method for purifying factor VIII and preparations obtained | |
PT81418A (en) | Process to obtain antibodies for human non-small lung cell carcinomas | |
Kotite et al. | Subunit structure of rabbit testosterone estradiol-binding globulin. | |
Camargo et al. | Conversion and inactivation of opioid peptides by rabbit brain endo-oligopeptidase A | |
KR860008270A (ko) | α-인터페론의 제조 및 정제 방법 | |
AUPM772494A0 (en) | Improvements in production of proteins in host cells | |
US2996428A (en) | Process for the manufacture of acth by cmc chromatography |